Over the past three months, Arbutus Biopharma Corporation [ABUS] ended the trading day at $4.01 and exhibited a change of 1.90% with a 24 hour trading and reached upto the volume of 1.94M compared to its recorded trading volume of 1.52 million. ABUS generated a 1 year amount change with 74.34%. Though for Principal markets a year is counted as a long time period. By having a look at the most recent performance of this stock, in the last week its amount moved by 4.51% with an amount shift of 36.33% over the last month.
On 16, November 2020, Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects. According to news published on Yahoo Finance, Data released today expands on November 15, 2020 AASLD presentation.
Analyst Birdseye View:
The most recent analyst activity for Arbutus Biopharma Corporation [NASDAQ:ABUS] stock was on July 24, 2020, when it was Downgrade with a Neutral rating from Robert W. Baird. Before that, on July 27, 2020, JMP Securities Recapitulated a Mkt outperform rating and elevated its amount target to $8. On May 19, 2020, Wedbush Upgrade an Outperform rating. On March 06, 2020, Chardan Capital Markets Upgrade a Buy rating and increased its price target to $5. On February 20, 2020, Robert W. Baird Initiated an Outperform rating and increased its price target to $8. On February 05, 2020, JMP Securities Upgrade a Mkt outperform rating and boosted its amount on this stock to $10. On October 07, 2019, B. Riley FBR Reiterated a Buy rating and decreased its target amount on this stock from $7 to $3.
In the past 52 weeks of trading, this stock has oscillated between a low of $0.88 and a peak of $9.02. Right now, according to Wall Street analyst the average 12-month amount target is $6.40. At the most recent market close, shares of Arbutus Biopharma Corporation [NASDAQ:ABUS] were valued at $4.01. According to the average price forecast, investors can expect a potential return of 8.57%.
Arbutus Biopharma Corporation [NASDAQ:ABUS] most recently reported quarterly sales of 1.52 billion, which represented growth of -51.60%. This publicly-traded organization’s revenue is $75,138 per employee, while its income is -$1,921,538 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -92.20, -112.63, -48.32 and -104.22 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 23.50 and the whole liability to whole assets at 21.18. It shows enduring liability to the whole principal at 23.15 and enduring liability to assets at 0.21 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 3.87 points at 1st support level, the second support level is making up to 3.80. But as of 1st resistance point, this stock is sitting at 4.05 and at 4.16 for 2nd resistance point.
Arbutus Biopharma Corporation [ABUS] reported its earnings at -$0.27 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.22/share signifying the difference of -0.05 and -22.70% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.25 calling estimates for -$0.24/share with the difference of -0.01 depicting the surprise of -4.20%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Arbutus Biopharma Corporation [NASDAQ:ABUS] is 15.90. Likewise, the Quick ratio is also the same, showing Cash ratio at 11.60. Now if looking for a valuation of this stock’s amount to sales ratio it’s 26.40.
The most recent insider trade was by McElhaugh Michael J., Chief Business Officer, and it was the sale of 20000.0 shares on Jul 23.